Clinical Characteristics of Aggressive NK-Cell Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.04.015
- Author:
Yi LIAO
1
;
He-Sheng HE
1
;
Yuan-Feng WEI
1
;
Da-Peng SHEN
1
;
Xin-Yue JI
1
;
Chen HUANG
1
;
Jun HUANG
1
;
Xiao-Ke JIN
1
;
Dong-Ping HUANG
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu 241000, Anhui Province, China.
2. Department of Hematology, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu 241000, Anhui Province, China.E-mail: hdp_9713@163.com.
- Publication Type:Journal Article
- Keywords:
flow cytometry;
programmed cell death protein-1;
aggressive NK-cell leukemia
- MeSH:
Male;
Female;
Humans;
Middle Aged;
Aged;
Retrospective Studies;
Leukemia, Large Granular Lymphocytic;
Leukemia, Prolymphocytic, T-Cell;
Prognosis;
Lymphohistiocytosis, Hemophagocytic
- From:
Journal of Experimental Hematology
2023;31(4):1026-1031
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore and summarize the clinical characteristics and treatment of aggressive NK-cell leukemia (ANKL), and provide new insights for clinical diagnosis and treatment of this disease.
METHODS:The clinical data of 7 patients with ANKL admitted to the First Affiliated Hospital of Wannan Medical College from March 2014 to July 2021 were retrospectively analyzed, and their clinical characteristics, laboratory and imaging results, treatment and outcomes were analyzed.
RESULTS:Among the 7 patients, 5 were males and 2 were females, with a median age of 47 (33-69) years old. The morphology of bone marrow cells in 7 patients showed similar large granular lymphocytes. Immunophenotyping revealed abnormal NK cells in 5 cases. By the end of follow-up, 6 cases died and 1 case survived, with a median survival time of 76.9 (4-347) days.
CONCLUSION:ANKL is a rare disease with short course and poor prognosis. If combined with hemophagocytic syndrome (HPS), the prognosis is even worse. There is no unified treatment method at present, and the use of PD-1 inhibitors may prolong the survival in some patients.
